Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE

by | Feb 24, 2023

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of the patient enrollment in the company’s pivotal phase 3 clinical study SPARKLE with the lead candidate drug Orviglance®. 

Press inquiries should be adressed to:

Søren Lemonius

Managing General Partner